MedPath

To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients

Not Applicable
Terminated
Conditions
Subdural Hematoma, Traumatic
Interventions
Device: Temperature management Zoll Intravascular Temperature Management device
Registration Number
NCT02064959
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

This randomized, prospective trial will study the effect of very early cooling in patients undergoing surgical evacuation of acute subdural hematomas (35°C prior to opening the dura followed by maintenance at 33°C for a minimum of 48h). Intravascular cooling catheters (Thermogard XP Device, Zoll) will be utilized to induce hypothermia or to maintain normothermia.

The primary objective is to determine if rapid induction of hypothermia prior to emergent craniotomy for traumatic subdural hematoma (SDH) will improve outcome as measured by Glasgow Outcome Scale-Extended (GOSE) at 6 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Non-penetrating traumatic brain injury
  • Glasgow Coma Scale (GCS) motor score ≤5 (not following commands)
  • Estimated or known age 22-65 years
  • Acute subdural hematoma requiring emergent craniotomy within 6 hours of initial injury
  • Estimated time of injury to time to reach temp of 35°C<6 hrs
Exclusion Criteria
  • Total GCS = 3 and bilateral fixed and dilated pupils
  • Following commands after an initial period of coma (GSC motor score of 6)
  • Known pre-existing neurological deficit (e.g., previous traumatic brain injury (TBI), stroke)
  • Concomitant spinal cord injury
  • Arrival temperature is <35°C
  • Hemodynamic instability (i.e., mean arterial pressure (MAP)<60 millimetres of mercury (mmHg) for 30 minutes)
  • Active cardiac dysrhythmia resulting in hemodynamic instability
  • Pregnancy
  • Duret hemorrhage
  • Prisoner or Ward of the State
  • Known history of clotting disorder (e.g., heparin induced thrombocytopenia, pulmonary embolism/deep venous thrombosis)
  • Injury to other body organ where hypothermia would be precluded because of bleeding risk (e.g., grade 3 liver laceration; bowel laceration; flail lung or international normalized ratio (INR) >1.4)
  • Inability to obtain informed consent or utilize exception to informed consent for emergency research.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HypothermiaTemperature management Zoll Intravascular Temperature Management deviceHypothermia to 33°C
NormothermiaTemperature management Zoll Intravascular Temperature Management devicestandard care - normothermia (37°C)
Primary Outcome Measures
NameTimeMethod
Number of Participants With Favorable Glasgow Outcome Score-Extended (GOS-E) at 6 Months Post Injury6 months post injury

Participants were monitored for 6 months after injury, and GOS-E was scored as favorable (moderate disability to good recovery) or unfavorable (severe disability, vegetative state, or death) at 6 months post-injury.

Secondary Outcome Measures
NameTimeMethod
Safety as Assessed by Number of Adverse Events Reported Per Participant6 months post injury

Adverse events were graded according to the USDHHS Common Terminology Criteria for Adverse Events V4.0. Serious adverse events and pre-defined adverse events of interest that historically were known to be of concern with hypothermia treatment were selected to be monitored and reported regardless of grade. These included cardiac arrhythmias, thromboembolic events, pneumonia, bleeding or hemorrhage, intraoperative hemorrhage, infection (culture positive, e.g., blood stream infection, urinary tract infection, ventriculitis), device-related infection, and death. The number of adverse events per participant were compared between groups.

Hospital Length of Stayfrom hospital admission to hospital discharge (median of about 18 to 21 days)
Intensive Care Unit (ICU) Length of Stayfrom ICU admission to ICU discharge (median of about 11 to 13 days)
Incidence of Cortical Spreading Depolarization6 months

Trial Locations

Locations (14)

Nagasaki University Hospital

🇯🇵

Nagasaki, Japan

Saiseikai Fukuoka General Hospital

🇯🇵

Fukuoka, Japan

Nippon Medical School Tamanagayama Hospital

🇯🇵

Tokyo, Japan

The University of Texas at Houston Medical School and Memorial Hermann Hospital

🇺🇸

Houston, Texas, United States

National Disaster Medical Center

🇯🇵

Tokyo, Japan

Kurume University Hospital

🇯🇵

Fukuoka, Japan

Kagawa University Hospital

🇯🇵

Kagawa, Japan

Nippon Medical School Hospital

🇯🇵

Tokyo, Japan

Yamaguchi University Hospital

🇯🇵

Yamaguchi, Japan

The University off Miami and Ryder Trauma Center, Jackson Memorial Hospital

🇺🇸

Miami, Florida, United States

The University of Pittsburgh Medical Center and UPMC Presbyterian

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Osaka Mishima Emergency Critical Care Center

🇯🇵

Osaka, Japan

© Copyright 2025. All Rights Reserved by MedPath